StocktoriaLongeveron Inc. LGVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $1.2M | $2.4M | $709,000 | $1.2M | $1.3M |
| Gross profit | $803,000 | $1.9M | $221,000 | $497,000 | $590,000 |
| Operating income | -$23.3M | -$16.5M | -$21.0M | -$18.0M | -$17.5M |
| Net income | -$22.7M | -$16.0M | -$21.4M | -$18.8M | -$17.0M |
| Operating cash flow | -$18.6M | -$13.9M | -$19.0M | -$14.0M | -$9.6M |
| Free cash flow | -$18.9M | -$14.5M | -$19.3M | -$14.5M | -$10.0M |
| Total assets | $10.3M | $25.6M | $12.1M | $27.4M | $42.8M |
| Total liabilities | $4.6M | $3.7M | $5.3M | $6.9M | $5.3M |
| Shareholders' equity | $5.7M | $21.9M | $6.7M | $20.5M | $37.5M |
| Ratios | |||||
| Gross margin | 67.0% | 78.8% | 31.2% | 40.7% | 45.2% |
| Operating margin | -1942.2% | -690.7% | -2966.0% | -1476.5% | -1336.6% |
| Net margin | -1893.6% | -667.8% | -3020.2% | -1541.3% | -1305.1% |
| FCF margin | -1575.5% | -607.1% | -2722.6% | -1189.7% | -763.1% |
| Return on assets | -221.3% | -62.5% | -177.3% | -68.7% | -39.9% |
| Return on equity | -400.1% | -73.0% | -317.7% | -91.9% | -45.5% |
| Current ratio | 1.33 | 7.60 | 1.50 | 4.17 | 13.06 |
| Revenue growth | -49.9% | 237.4% | -42.0% | -6.4% | 2274.5% |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001721484 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.